Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitomycin C: a clinical update.

W T Bradner1

  • 1Research Advisors, 4903 Briarwood Circle, Manlius, New York 13104, USA.

Cancer Treatment Reviews
|March 10, 2001
PubMed
Summary
This summary is machine-generated.

Mitomycin C remains valuable for bladder cancer but its role in other cancers like breast and lung needs redefinition. Newer treatments are impacting its use in cervical, gastric, and pancreatic cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiotic induced bacterial challenge of irradiated mice.

Antibiotics & chemotherapy (Northfield, Ill.)·2014
Same author

Experimental tumor inhibitory and toxic properties of the mitomycin A analogue 7-(2-hydroxyethoxy) mitosane (BMY-25551).

Anticancer research·1992
Same author

Phase I trial of FK973: description of a delayed vascular leak syndrome.

Investigational new drugs·1991
Same author

Antitumor and DNA-binding properties of a group of oligomeric complexes of Pt(II) and Pt(IV).

Journal of medicinal chemistry·1990
Same author

Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent.

Investigational new drugs·1990
Same author

Cyclic acetal derivatives of mitomycin C.

The Journal of antibiotics·1990
Same journal

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026
Same journal

Treatment of breast cancer brain metastases in the era of novel drugs.

Cancer treatment reviews·2026
Same journal

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same journal

Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer.

Cancer treatment reviews·2026
Same journal

Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.

Cancer treatment reviews·2026
Same journal

Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes.

Cancer treatment reviews·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Mitomycin C was previously reviewed 25 years ago.
  • An update on its clinical utility is warranted given advancements in cancer treatment.

Purpose of the Study:

  • To reassess the clinical usefulness of Mitomycin C.
  • Evaluate its single-agent activity and combination efficacy in various neoplastic diseases.

Main Methods:

  • Review of representative publications and clinical trials globally.
  • Reassessment of single-agent activity across major cancers.
  • Evaluation of key combination regimens.

Main Results:

  • Definite role in localized bladder cancer.
  • Active but requires redefinition in breast, head and neck, and non-small cell lung cancers.

Related Experiment Videos

  • Active but being displaced in cervical, gastric, and pancreatic cancers; likely no longer valuable in colon cancer.

    • Conclusions:

    • Mitomycin C retains a role in specific cancers, notably bladder cancer.
    • Its utility in other malignancies requires ongoing investigation and redefinition.
    • The emergence of newer therapies necessitates continuous re-evaluation of Mitomycin C's therapeutic role.